Summary: Axsome Therapeutics In. is set to present multiple studies on AXS-12 and solriamfetol at Sleep Europe 2024, the 27th Congress of the European Sleep Research Society. These presentations include topline results from the phase 3 SYMPHONY trial of AXS-12 for narcolepsy, … [Read more...]
Zevra to Present Phase 2 Data on KP1077 for Idiopathic Hypersomnia
Summary: Zevra Therapeutics announced that Rene Braeckman, PhD, the company’s senior vice president of clinical development, will present top-line data from the phase 2 clinical trial of KP1077 (serdexmethylphenidate) in patients with idiopathic hypersomnia (IH) at Sleep Europe … [Read more...]
Alkermes to Present Data on ALKS 2680 for Narcolepsy Type 2 and Idiopathic Hypersomnia
Summary: Alkermes plc is set to present data from its phase 1b study of ALKS 2680, a novel oral orexin 2 receptor agonist, at Sleep Europe 2024. The study evaluated ALKS 2680 in patients with narcolepsy type 2 and idiopathic hypersomnia, showing improved wakefulness compared to … [Read more...]
Alkermes to Present Data for ALKS 2680 in Narcolepsy Treatment | Sleep Review
Summary: Alkermes plc introduced plans to present 3 posters at Rest 2024, showcasing the probable positive aspects of its investigational orexin 2 receptor agonist, ALKS 2680, for narcolepsy therapy. Displays will consist of information from a period 1b research, the layout of … [Read more...]
Avadel to Present Data on Lumryz for Narcolepsy at SLEEP 2024
Summary: At Sleep 2024, Avadel will present new data on Lumryz, the initially extended-launch, when-nightly formulation of sodium oxybate for narcolepsy. Findings highlighted client preference for Lumryz around twice-nightly oxybate, with 94% preferring when-nightly dosing and … [Read more...]
Defined Sleep to Present Latest CBD Sleep Supplement Research
Summary: Described Snooze, a developer of CBD rest nutritional supplements, will showcase its newest investigation at the American Psychiatric Affiliation (APA) 2024 Once-a-year Conference in New York Town. Led by Paul Muchowski, PhD, the staff will highlight proof-based tactics … [Read more...]
Zevra to Present Data from KP1077 Phase 2 Trial in IH at SLEEP
Summary: At Slumber 2024, Zevra Therapeutics will existing the whole information from the KP1077 section 2 trial for idiopathic hypersomnia, signaling potential progress into stage 3 trials. A shareholder letter from CEO Neil McFarlane underscores this milestone, alongside … [Read more...]